Transcription of Biogen Safe Harbor Statement - eisai.co.jp
{{id}} {{{paragraph}}}
2017 12 21 BAN2401 II 18 ADCOMS 12 18 CEO (Nasdaq: BIIB CEO ) A BAN2401 856 II 201 12 18 2018 201 identifier NCT01767311 A futility 16 18 12 BAN2401 5 ADCOMS Alzheimer s Disease Composite Score Clinically Significant Difference BAN2401 25 80 18 ADCOMS CDR-SB Clinical Dementia Rating Sum of Boxes PET vMRI Dr.
Biogen Safe Harbor Statement This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 about results from the Phase 2 study of
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}